For the quarter ending 2025-09-30, BCAB had -$9,887K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -15,778 | -34,045 |
| Depreciation and amortization | 56 | 298 |
| Change in fair value of warrant liability | 2,119 | -1,583 |
| Stock-based compensation | 1,292 | 3,022 |
| Prepaid expenses and other assets | -1,056 | 383 |
| Accounts payable and accrued expenses | 1,016 | 2,535 |
| Accounts payable and accrued expenses - related parties | 0 | - |
| Right-of-use assets and lease liabilities, net | 358 | -252 |
| Net cash used in operating activities | -9,881 | -30,408 |
| Payment of financing costs | 0 | 444 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 47 |
| Payments for taxes related to net settlement of equity awards | 6 | 34 |
| Net cash provided by (used in) financing activities | -6 | -431 |
| Net decrease in cash and cash equivalents | -9,887 | -30,839 |
| Cash and cash equivalents at beginning of period | 49,046 | - |
| Cash and cash equivalents at end of period | 8,320 | - |
BioAtla, Inc. (BCAB)
BioAtla, Inc. (BCAB)